La vendita allo scoperto per Dolphin Entertainment dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Dolphin Entertainment. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Dolphin Entertainment (NASDAQ:DLPN) Azioni, Report sulle vendite allo scoperto

Dolphin Entertainment

Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.

Dolphin Entertainment, Inc. - Common Stock

Dolphin Entertainment Inc

WIIM

VYGR

Voyager Technologies shares are trading lower. The stock may be pulling back after its recent post-IPO surge.

<a href="https://www.youtube.com/watch?v=5dmFa9iXPWI">https://www.youtube.com/watch?v=5dmFa9iXPWI</a>
&nbsp;

News

MSFT

Live At AMD Advancing AI Keynote, OpenAI CEO Sam Altman Says Using AMD's MI300x And MI450 AI Chips

<ul>
<li>Supermicro launches highly optimized AI solutions, based on AMD Instinct MI350 Series GPUs and AMD ROCm&#x2122; Software, delivering breakthrough inference performance and power efficiency.</li>
<li>The new Supermicro H14 GPU solutions are powered by the newest 4th generation AMD CDNA&#x2122; architecture, delivering optimized performance and efficiency for large AI training models and high-speed inference workloads</li>
<li>Large memory capacity with 2.304TB total HBM3e per 8-GPU server which delivers faster computation and more efficient scaling for AI, inferencing, and training</li>
</ul>
SAN JOSE, Calif., June 12, 2025 /PRNewswire/ -- Supermicro, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>), a Total IT Solution Provider for AI, Cloud, Storage, and 5G/Edge, is announcing that both liquid-cooled and air-cooled GPU solutions will be available with the new AMD Instinct MI350 series GPUs, optimized for unparalleled performance, maximum scalability, and efficiency. The Supermicro H14 generation of GPU optimized solutions featuring dual AMD EPYC&#x2122; 9005 CPUs along with the AMD Instinct MI350 series GPUs, are designed for organizations seeking maximum performance at scale, while reducing the total cost of ownership for their AI-driven data centers.

SMCI

Supermicro Unveils H14 GPU Solutions Powered By AMD Instinct MI350 Series And EPYC CPUs, Delivering Breakthrough AI Performance, Efficiency, And Scalability For Next-Gen Inference And Training

GE Aerospace shares are trading lower in sympathy with Boeing following the crash of an Air India flight.

FRST

Primis Financial Expects To Record An Additional Gain Of Between $6.5M-$7M Pre-Tax As The Sales Price Per Share Exceeded The Carrying Value As Of March 31, 2025

Primis Financial Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRST#NASDAQ">FRST</a>) ("Primis" or the "Company") today reported a signed non-binding term sheet to sell a portion of its ownership in Panacea Financial Holdings, Inc. ("PFH" or "Panacea"). This proposed sale follows the deconsolidation of PFH at March 31, 2025 and is expected to generate proceeds to the Company of approximately $22 million. Additionally, the Company expects to record an additional gain of between $6.5 and $7.0 million pre-tax as the sales price per share exceeded the carrying value as of March 31, 2025.

Primis Financial Reports Signed Non-Binding Term Sheet To Sell Portion Of Its Ownership In Panacea Financial Holdings; Expects Proceeds Of ~$22M To The Company

— Only AMD powers the full spectrum of AI, bringing together leadership GPUs, CPUs, networking and open software to deliver unmatched flexibility and performance —
— Meta, OpenAI, xAI, Oracle, Microsoft, Cohere, HUMAIN, Red Hat, Astera Labs and Marvell discussed how they are partnering with AMD for AI solutions —
SANTA CLARA, Calif., June 12, 2025 (GLOBE NEWSWIRE) -- AMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) delivered its comprehensive, end-to-end integrated AI platform vision and introduced its open, scalable rack-scale AI infrastructure built on industry standards at its 2025 Advancing AI event.
AMD and its partners showcased:
<ul>
<li>How they are building the open AI ecosystem with the new AMD Instinct&#x2122; MI350 Series accelerators</li>
<li>The continued growth of the AMD ROCm&#x2122; ecosystem</li>
<li>The company's powerful, new, open rack-scale designs and roadmap that bring leadership rack-scale AI performance beyond 2027</li>
</ul>

MRVL

ORCL

AMD Unveils Vision For An OpenAI Ecosystem, Detailing New Silicon, Software And Systems At Advancing AI 2025

SAIL

SailPoint shares are trading higher after multiple analysts raised their price targets on the stock. The company recently reported better-than-expected Q1 adjusted EPS results and issued Q2 guidance above estimates. Also, the company raised its FY26 guidance above estimates.

Health Secretary&nbsp;Robert F. Kennedy Jr.&nbsp;named eight new members to the CDC&#8217;s Advisory Committee on Immunization Practices on Wednesday, including several anti-vaccine proponents, after&nbsp;<a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45898417/rfk-jr-appoints-vaccine-critics-to-cdc-vaccine-panel-after-firing-entire-advisory-committee-report" rel="noreferrer noopener">dismissing all 17 existing advisers</a>.
Kennedy justified the overhaul to &#8220;re-establish public confidence in vaccine science,&#8221; claiming, without providing specific evidence, that prior Biden-appointed members had conflicts of interest. The new eight-member committee represents the minimum allowed under ACIP&#8217;s founding charter.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/43166965/senate-hearings-loom-as-robert-f-kennedy-faces-scrutiny-over-conflicts-of-interest-in-mercks-gardasil-vaccine-litigation" rel="noreferrer noopener">RJK Jr.&#8217;s Involvement In Merck Lawsuit Faces Scrutiny Ahead Of Senate Hearing</a>
Martin Kulldorff, a biostatistician and epidemiologist, was among eight individuals selected by Kennedy to join the Advisory Committee on Immunization Practices (ACIP).
Kulldorff has been an outspoken critic of COVID-19 lockdowns and vaccine mandates.
His appointment has also raised questions due to his paid involvement in litigation against a major vaccine manufacturer, <a href="https://www.yahoo.com/news/exclusive-kennedys-vaccine-adviser-expert-152349812.html">according</a> to Reuters.
Citing court records, Reuters notes that Kulldorff served as an expert witness in lawsuits against Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) over its Gardasil vaccine, which is used to prevent cancers caused by the human papillomavirus (HPV).
The plaintiff accused the pharmaceutical company of not properly disclosing the vaccine&#8217;s risks.
Gardasil was approved in the U.S. in 2006 after going through clinical trials to prove its safety and efficacy.
During a deposition in October, Kulldorff acknowledged that he had been paid $400 an hour for his work on the case and had billed approximately $33,000 through September.
He also received a $4,000 retainer in connection with the North Carolina lawsuit, which was part of a broader legal effort encompassing about 200 related cases. In March, a federal judge ruled in favor of Merck in that particular case.
Kulldorff&#8217;s paid role as a litigation consultant could conflict with ACIP&#8217;s established rules. According to the committee&#8217;s guidelines, members are prohibited from serving as paid expert witnesses or litigation consultants in cases involving vaccine manufacturers while actively serving on the panel.
Gardasil/Gardasil 9 sales declined 41% to $1.33 billion in the first quarter of 2025, primarily due to lower demand in China, partially offset by higher demand in most international regions, particularly in Japan, and higher pricing and demand in the U.S. Excluding China, sales grew 14%, or 16%, excluding the <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44983460/mercks-q1-earnings-beat-wall-street-adjusts-2025-profit-outlook-as-tariffs-may-result-in-incremental-cost-of-200-million" rel="noreferrer noopener">impact of foreign exchange</a>.
Price Action: MRK stock was up 1.87% at $81.82 at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/06/45876082/nih-revolts-scientists-decry-budget-cuts-rfk-jr-political-interference-warn-of-long-term-public-heal" target="_blank" rel="noreferrer noopener">NIH Revolts: Scientists Decry Budget Cuts, RFK Jr. Political Interference, Warn Of Long-Term Public Health Damage</a></li>
</ul>
Photo: Shutterstock

Large Cap

Health Care

RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit

Infobell delivers highly performant AI solutions with AMD Instinct&#x2122; GPUs and AMD EPYC&#x2122; CPUs, ensuring exceptional scalability within an open ecosystem to meet the evolving needs of AI innovation.
Infobell IT Solutions Pvt. Ltd. ("Infobell"), a global leader in product engineering and AI solutions, today announced an expanded collaboration with AMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) to drive enterprise-ready AI innovation powered by AMD Instinct&#x2122; GPUs and AMD EPYC&#x2122; CPUs.
As a long-standing engineering and solutions partner to AMD, Infobell leverages the AMD CDNA architecture and ROCm&#x2122; software stack to deliver high-performance AI, cloud, and high-performance computing (HPC) solutions to leading enterprises and cloud service providers worldwide.
Infobell is also a proud sponsor of the AMD Advancing AI 2025, underscoring its commitment to accelerating AI adoption with AMD technologies.

Infobell Expands Collaboration With AMD To Deliver Scalable, High-Performance AI Solutions Using AMD Instinct GPUs And EPYC CPUs

<a href="https://www.youtube.com/watch?v=5dmFa9iXPWI " title="https://www.youtube.com/watch?v=5dmFa9iXPWI ">https://www.youtube.com/watch?v=5dmFa9iXPWI&nbsp;</a>
&nbsp;

AMD CEO Introduces 'Vulcano' Chip For AI Networking

Macro Economic Events

Economics

NVDA

Live On CNN, Nvidia CEO Reportedly Says Will Stop Including China In Its Forecasts Amid U.S. Chip Export Controls

AMD CeO Announces MI400 Series Chips, Available In 2026

Telsey Advisory Group analyst Dana Telsey reiterated the Market Perform rating on Victoria&#8217;s Secret &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) <a target="_blank" href="https://www.benzinga.com/quote/VSCO/analyst-ratings" rel="noreferrer noopener">with a price forecast of $24</a>.
On Wednesday, the company reported first-quarter adjusted earnings per share of 9 cents, which is in line with the analyst consensus estimate. Quarterly sales of $1.35 billion (flat year over year) also <a href="https://www.benzinga.com/markets/earnings/25/06/45887760/pink-power-tariff-trouble-victorias-secret-battles-flat-sales-rising-costs" target="_blank" rel="noreferrer noopener">came in line with the Street view</a>.
Victoria&#8217;s Secret has lowered its fiscal year 2025 adjusted operating income guidance to a range of $270 million to $320 million, down from its prior forecast of $300 million to $350 million.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/23/05/32558345/victorias-secret-navigating-unsettled-macro-environment-analyst-lowers-expectations" rel="noreferrer noopener">Victoria&#8217;s Secret Navigating Unsettled Macro Environment, Analyst Lowers Expectations</a>
The company also forecasts second-quarter sales between $1.38 billion and $1.41 billion, slightly below the $1.42 billion estimate.
Telsey noted that while second-quarter sales guidance was roughly in line with expectations, profit forecasts lagged prior consensus, which had already factored in a $10 million cybersecurity-related hit and another $10 million from tariffs.
Given ongoing macro pressures and uncertainty around the full-year tariff impact, the analyst remains cautious on the company, acknowledging progress in product and messaging but highlighting the continued need for brand repositioning in a competitive, slow-growth market.
Telsey pointed out that while Victoria&#8217;s Secret has taken steps to soften the blow from tariffs, higher rates, assumed at 30% for China and 10% elsewhere, will still have an effect in the second quarter and beyond, compared to assumptions made in the March fiscal year 2025 outlook.
The company expects a $120 million gross tariff impact for the year, with $70 million already mitigated, leaving a $50 million net hit that could shave over 100 basis points off gross margin, including a $10 million drag in the second quarter due to timing limitations.
The remainder is expected to be spread fairly evenly between the third quarter and fourth quarter.
The analyst noted that Victoria&#8217;s Secret has worked with suppliers to cut costs, diversify sourcing, reduce reliance on China (now in the low-single digits), improve shipping efficiency, and shift from blanket discounts to more targeted promotions like gift-with-purchase events.
Telsey lowered estimates, now projecting fiscal year 2025 EPS of $2.10, down from its prior $2.22 forecast.
For fiscal year 2026, the analyst expects EPS of $2.25, revised from $2.38 earlier and slightly below the prior consensus of $2.31.
Price Action: VSCO shares are trading lower by 5.48% to $19.85&nbsp;at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45898118/victorias-secret-expects-50-million-tariff-hit-in-2025-cfo-scott-sekella-says-q4-to-bear-largest-dollar-hit" target="_blank" rel="noreferrer noopener">Victoria&#8217;s Secret Expects $50 Million Tariff Hit In 2025 — CFO Scott Sekella Says Q4 To Bear Largest Dollar Hit</a></li>
</ul>
Photo by JHVEPhoto via Shutterstock

Analyst Color

Equities

Price Target

Reiteration

Markets

Analyst Ratings

Trading Ideas

General

VSCO

Victoria's Secret Analyst Flags Profit Pressure, Keeps Rating Amid Tariff And Cyber Headwinds

<a href="https://www.youtube.com/watch?v=5dmFa9iXPWI">https://www.youtube.com/watch?v=5dmFa9iXPWI</a>
&nbsp;
&nbsp;

AMD CEO Announces 'Helios' Artificial Intelligence Server

ROKU

Roku shares are trading lower. The stock may be pulling back after rising in recent sessions.

Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) on Thursday released results from APPULSE-PNH, a Phase 3B study evaluating the efficacy and safety of twice-daily oral monotherapy Fabhalta (iptacopan) in adult patients with <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">paroxysmal nocturnal hemoglobinuria (PNH)</a> with Hb levels ≥10g/dL who switched from anti-C5 therapies (eculizumab or ravulizumab).
The company released topline <a target="_blank" href="https://www.benzinga.com/24/12/42370119/novartis-touts-encouraging-data-from-late-stage-study-for-fabhalta-in-rare-type-of-blood-disorder" rel="noreferrer noopener">data in December 2024</a>.
What Happened: PNH is a rare complement-mediated blood disorder. People with PNH have an acquired mutation in some of their hematopoietic stem cells that causes them to produce RBCs susceptible to premature destruction.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/45075714/novartis-q1-earnings-beat-street-view-ceo-confident-to-deliver-upgraded-2025-guidance" rel="noreferrer noopener">Novartis Q1 Earnings Beat Street View, CEO &#8216;Confident&#8217; In Delivering Upgraded Guidance</a>
This leads to intravascular hemolysis (destruction of RBCs within blood vessels) and extravascular hemolysis (destruction of RBCs mostly in the spleen and liver).
After 24 <a target="_blank" href="https://www.novartis.com/news/media-releases/novartis-fabhalta-shows-statistically-significant-and-clinically-meaningful-improvements-hemoglobin-new-population-patients-pnh" rel="noreferrer noopener">weeks</a> of treatment with Fabhalta, the Hb level improved&nbsp;on average by 2.01 g/dL, with most patients achieving normal or near-normal levels.
Data will be presented at the European Hematology Association (EHA) Congress 2025.
No patients required transfusion during the study, and the vast majority (92.7%) achieved Hb ≥12g/dL, reaching normal or near-normal levels. Patients treated with Fabhalta also reported clinically meaningful improvements in fatigue (as measured by FACIT-Fatigue score) through Day 168, reaching absolute levels similar to those reported in the general population.
Furthermore, patients treated with Fabhalta maintained intravascular hemolysis control and resolved extravascular hemolysis control, as demonstrated by lactate dehydrogenase levels (&lt;1.5 upper limit of normal) and a reduction in absolute reticulocyte count.
Alongside APPULSE-PNH, longer-term data from patients initially included in the APPLY-PNH and APPOINT-PNH Phase 3 studies will be presented at EHA.
Why It Matters: Novartis says Anti-C5 therapies, including AstraZeneca Plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) Soliris (eculizumab) or Ultomiris (ravulizumab), are commonly administered every two to eight weeks as intravenous infusions, and treatment visits (including journey, waiting, infusion and recovery time) can take approximately four to five hours.
Despite treatment with anti-C5 therapies, a large proportion of people with PNH remain anemic, and some are dependent on blood transfusions.
NVS Price Action: NVS stock is up 2.17% at $120.54 at publication on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/01/42978906/regeneron-pipeline-aims-to-address-220-billion-therapeutic-opportunities-by-2030" target="_blank" rel="noreferrer noopener">Regeneron Pipeline Aims To Address $220 Billion Therapeutic Opportunities By 2030</a></li>
</ul>
Photo: Shutterstock

Biotech

Movers

Novartis' Fabhalta Delivers Hemoglobin Gains, Reduces Fatigue In Patients With Rare Blood Disorder

WINT

Windtree Therapeutics shares are trading lower. The company on Wednesday announced it received an offer for its preclinical oncology drug candidate.

Catheter Precision, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#NYSE">VTAK</a>), a U.S.-based innovative medical device company focused on electrophysiology products, is issuing this press release in response to recent increases in trading activity in its common stock. The Company is not aware of any information related to the Company or its operations that it would have expected to cause increased market activity. The Company continues to pursue its strategic plans as previously disclosed, including its ongoing efforts to secure financing to meet its liquidity needs.

VTAK

Catheter Precision Addresses Increased Trading Activity, Reaffirms Strategic Plans

JBLU

RYAAY

SKYW

Shares of airline companies are trading lower after an Air India 787-8 Dreamliner crashed near the Ahmedabad airport.

Press Releases

Longtime Shore Fire Media Client Cyndi Lauper To Be Inducted Into Rock & Roll Hall of Fame

Dolphin Clients Shine at the 2025 Met Gala

Dolphin to Host First Quarter 2025 Earnings Call on May 13 at 4:30 PM ET

Dolphin Subsidiary The Digital Dept. Sees Surge In Affiliate Marketing Division, Driving Over $6.6 Million In Gross Retail Sales In First Quarter

Earnings

Dolphin Reports Q1 2025 Results; Core Entertainment Publicity and Marketing Segment (EPM) Revenue Up 2% YoY to $12.1 Million, Strategic Investments and New Division Launch to Drive Long-Term Growth

Dolphin Subsidiary Special Projects Curates Star-Studded Guest List for the Tory Burch Store Opening on Rodeo Drive

Shore Fire Media Clients Shape the Summer 2025 Season With Star-Studded Music Festivals and Concert Series

Dolphin to Present at Maxim Group's 2025 Virtual Tech Conference

Dolphin Subsidiary Special Projects Partners with The Peabody Awards on 2025 Awards Ceremony

Dolphin Subsidiaries Shore Fire Media and The Digital Dept. Take Over CMA Fest 2025

DLPN

Anghami

BloomZ

Brera Holdings PLC - Class B Ordinary Shares

Brera Holdings

Cineverse

Pop Culture Group Co., Ltd - Class A Ordinary Shares

Pop Culture Gr

Gaia

Global Mofy AI Limited - Class A Ordinary Shares

Global Mofy AI

Kuke Music Holding Limited American Depositary Shares (each representing ten (10) Class A Ordinary Shares)

Kuke Music Hldg

LiveOne

Moving iMage Technologies, Inc. Common Stock

Moving iMage Technologies

Mega Matrix

NIP Group Inc. - American Depositary Shares

NIP Group

PodcastOne

Reading International Inc - Class A Non-voting Common Stock

Reading Intl

Scienjoy Holding Corporation - Class A Ordinary Shares

Scienjoy Holding

Sound Group Inc. - American Depositary Shares

Comments

Dolphin Entertainment

Vendite allo scoperto

Dolphin Entertainment (NASDAQ:DLPN) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO